IL2 and neoplasm: DCs take up tumor antigens and migrate to lymph nodes to activate the IL-2-producing CD4+ (Th1) and tumor-specific CD8+ (Th2) T cells, which migrate to the tumor site and eradicate the viable antigen-positive tumor cells.